BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 21832154)

  • 1. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
    Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
    Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
    Kim M; Kim M; Park SJ; Lee C; Lim DS
    EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation.
    Chan SW; Lim CJ; Guo F; Tan I; Leung T; Hong W
    J Biol Chem; 2013 Dec; 288(52):37296-307. PubMed ID: 24225952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiomotins link F-actin architecture to Hippo pathway signaling.
    Mana-Capelli S; Paramasivam M; Dutta S; McCollum D
    Mol Biol Cell; 2014 May; 25(10):1676-85. PubMed ID: 24648494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development.
    Hong W
    Sci Signal; 2013 Sep; 6(291):pe27. PubMed ID: 24003252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
    Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
    J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiomotin Family Members: Oncogenes or Tumor Suppressors?
    Lv M; Shen Y; Yang J; Li S; Wang B; Chen Z; Li P; Liu P; Yang J
    Int J Biol Sci; 2017; 13(6):772-781. PubMed ID: 28656002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein.
    DeRan M; Yang J; Shen CH; Peters EC; Fitamant J; Chan P; Hsieh M; Zhu S; Asara JM; Zheng B; Bardeesy N; Liu J; Wu X
    Cell Rep; 2014 Oct; 9(2):495-503. PubMed ID: 25373897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
    Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
    Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
    Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
    Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
    Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
    Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
    Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
    Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.
    Xiao L; Chen Y; Ji M; Dong J
    J Biol Chem; 2011 Mar; 286(10):7788-7796. PubMed ID: 21233212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth.
    Adler JJ; Heller BL; Bringman LR; Ranahan WP; Cocklin RR; Goebl MG; Oh M; Lim HS; Ingham RJ; Wells CD
    J Biol Chem; 2013 May; 288(21):15181-93. PubMed ID: 23564455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.
    Moleirinho S; Hoxha S; Mandati V; Curtale G; Troutman S; Ehmer U; Kissil JL
    Elife; 2017 May; 6():. PubMed ID: 28464980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.
    Shi Y; Geng D; Zhang Y; Zhao M; Wang Y; Jiang Y; Yu R; Zhou X
    J Mol Neurosci; 2019 May; 68(1):38-48. PubMed ID: 30771084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos.
    Hirate Y; Hirahara S; Inoue K; Suzuki A; Alarcon VB; Akimoto K; Hirai T; Hara T; Adachi M; Chida K; Ohno S; Marikawa Y; Nakao K; Shimono A; Sasaki H
    Curr Biol; 2013 Jul; 23(13):1181-94. PubMed ID: 23791731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.